BRIEF-Sobi says expands haemophilia B development portfolio

Reuters Staff

1 Min Read

Feb 16 (Reuters) - Swedish Orphan Biovitrum Ab (Publ)

* Sobi expands haemophilia B development portfolio by adding rFIXFc-XTEN to its collaboration agreement with Bioverativ Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)